S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
NASDAQ:BDSI

BioDelivery Sciences International (BDSI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$5.59
▼
$5.60
50-Day Range
$5.54
▼
$5.60
52-Week Range
$2.50
▼
$5.62
Volume
2.09 million shs
Average Volume
3.34 million shs
Market Capitalization
$577.05 million
P/E Ratio
6.74
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

BDSI stock logo

About BioDelivery Sciences International (NASDAQ:BDSI) Stock

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.


BDSI Stock News Headlines

September 14, 2023 | usnews.com
Florida International University
May 6, 2023 | usnews.com
International High School for Health Sciences
September 26, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
October 15, 2022 | omaha.com
International climate change bodies win humanity award
September 16, 2022 | thestreet.com
Perilous Reversal Watch: BioDelivery Sciences International (BDSI)
September 13, 2022 | npr.org
Science
May 10, 2022 | seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript
May 2, 2022 | thestreet.com
Jim Cramer's Top Stock Picks: DF MNST BDSI
September 26, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
April 5, 2022 | benzinga.com
Why Collegium Pharmaceutical's Shares Are Trading Higher Today
February 24, 2022 | finance.yahoo.com
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
February 24, 2022 | seekingalpha.com
BioDelivery Sciences launches migraine therapy in U.S.
February 24, 2022 | finance.yahoo.com
BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?
February 15, 2022 | stockhouse.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioDelivery Sciences International, Inc. Buyout
February 14, 2022 | apnews.com
BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders
February 14, 2022 | apnews.com
BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders
February 14, 2022 | finance.yahoo.com
BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium
February 7, 2022 | finance.yahoo.com
Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)
February 6, 2022 | nasdaq.com
BioDelivery Sciences International (NASDAQ:BDSI) Could Easily Take On More Debt
January 31, 2022 | finance.yahoo.com
Should Value Investors Pick BioDelivery (BDSI) Stock Now?
December 28, 2021 | finance.yahoo.com
Raleigh pharma gets favorable ruling in case for drug exclusivity
December 20, 2021 | fool.com
Why BioDelivery Sciences International Stock Was Up 28.5% Monday
December 3, 2021 | finance.yahoo.com
Why Is BioDelivery (BDSI) Down 20.8% Since Last Earnings Report?
November 17, 2021 | finance.yahoo.com
BioDelivery Sciences International, Inc. (BDSI)
November 15, 2021 | finance.yahoo.com
Biodelivery Sciences Intl Insider Makes $320K Stock Purchase
November 9, 2021 | nasdaq.com
Tuesday 11/9 Insider Buying Report: BDSI, BALY
November 3, 2021 | finance.yahoo.com
BioDelivery Sciences International (BDSI) Tops Q3 Earnings Estimates
See More Headlines
Receive BDSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.

BDSI Company Calendar

Last Earnings
11/02/2021
Today
9/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:BDSI
CUSIP
09060J10
CIK
1103021
Web
www.bdsi.com
Phone
(919) 582-9050
Fax
919-582-9051
Employees
200
Year Founded
1997

Profitability

EPS (Most Recent Fiscal Year)
$0.83
Trailing P/E Ratio
6.74
Forward P/E Ratio
14.71
P/E Growth
N/A
Net Income
$84.86 million
Net Margins
50.90%
Pretax Margin
17.77%
Return on Equity
21.25%
Return on Assets
10.56%

Debt

Debt-to-Equity Ratio
0.29
Current Ratio
2.45
Quick Ratio
2.17

Sales & Book Value

Annual Sales
$166.70 million
Price / Sales
3.46
Cash Flow
$0.36 per share
Price / Cash Flow
15.42
Book Value
$1.90 per share
Price / Book
2.94

Miscellaneous

Outstanding Shares
103,229,000
Free Float
92,927,000
Market Cap
$577.05 million
Optionable
Optionable
Beta
0.56

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Jeffrey Allen Bailey (Age 59)
    CEO & Director
    Comp: $599.96k
  • Mr. Scott M. Plesha (Age 57)
    Pres & Chief Commercial Officer
    Comp: $629.46k
  • Mr. James Vollins J.D.Mr. James Vollins J.D. (Age 53)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $586.68k
  • Dr. Thomas B. Smith FAAFP (Age 61)
    M.D., Chief Medical Officer
    Comp: $570.06k
  • Mr. John GolubieskiMr. John Golubieski (Age 57)
    CFO & Chief Accounting Officer
  • Mr. Joseph M. Lockhart
    Sr. VP of Operations
  • Mr. Kevin Ostrander
    Sr. VP of Bus. Devel.
  • Dr. Bill McCarberg
    Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Arthur G. Lipman PharmD
    Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Jeff Katz
    Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board

Key Competitors

View All Competitors













BDSI Stock - Frequently Asked Questions

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to analysts' expectations of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%. During the same quarter in the previous year, the business posted $0.09 EPS.

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $5.59.

How much money does BioDelivery Sciences International make?

BioDelivery Sciences International (NASDAQ:BDSI) has a market capitalization of $577.05 million and generates $166.70 million in revenue each year. The specialty pharmaceutical company earns $84.86 million in net income (profit) each year or $0.83 on an earnings per share basis.

How many employees does BioDelivery Sciences International have?

The company employs 200 workers across the globe.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The official website for the company is www.bdsi.com. The specialty pharmaceutical company can be reached via phone at (919) 582-9050, via email at matthew@lifesciadvisors.com, or via fax at 919-582-9051.

This page (NASDAQ:BDSI) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -